Cantor Fitzgerald Maintains Overweight on Krystal Biotech, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reaffirmed an Overweight rating on Krystal Biotech (NASDAQ:KRYS) and increased the price target from $160 to $180, indicating a positive outlook on the company's stock.
December 13, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock rating has been maintained at Overweight by Cantor Fitzgerald, with a raised price target from $160 to $180, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Josh Schimmer typically signals a strong conviction in the company's growth prospects and financial health. This can often lead to increased investor confidence and a potential short-term rise in the stock price, as market participants may adjust their valuations to align with the new analyst expectations.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100